

**Listing of Claims:**

1. (previously presented) An ApoA-I agonist compound comprising:
  - (i) a 15 to 26- residue peptide or peptide analogue according to formula (I) which forms an amphipathic  $\alpha$ -helix in the presence of lipids and exhibits at least about 38% LCAT activation activity as compared with human ApoA-I wherein one or two helical turns are deleted from formula (I), wherein a helical turn consists of 3 to 4 consecutive residues selected from residues  $X_1$  to  $X_{23}$  of formula (I):

$Z_1-X_1-X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9-X_{10}-X_{11}-X_{12}-X_{13}-X_{14}-X_{15}-X_{16}-X_{17}-X_{18}-X_{19}-X_{20}-X_{21}-X_{22}-X_{23}-Z_2$

or a pharmaceutically acceptable salt thereof, wherein:

- $X_1$  is Pro (P), Ala (A), Gly (G), Gln (Q), Asn (N), Asp (D) or D-Pro (p);
- $X_2$  is an aliphatic residue;
- $X_3$  is a Leu (L) or Phe (F);
- $X_4$  is Glu (E)
- $X_5$  is an aliphatic residue;
- $X_6$  is Leu (L) or Phe (F);
- $X_7$  is Glu (E) or Leu (L);
- $X_8$  is Asn (N) or Gln (Q);
- $X_9$  is Leu (L);
- $X_{10}$  is Leu (L), Trp (W) or Gly (G);
- $X_{11}$  is an acidic residue;
- $X_{12}$  is Arg (R);
- $X_{13}$  is Leu (L) or Gly (G);
- $X_{14}$  is Leu (L), Phe (F) or Gly (G);
- $X_{15}$  is Asp (D);
- $X_{16}$  is Ala (A);
- $X_{17}$  is Leu (L);
- $X_{18}$  is Asn (N) or Gln (Q);
- $X_{19}$  is a basic residue;
- $X_{20}$  is a basic residue;
- $X_{21}$  is Leu (L);
- $X_{22}$  is a basic residue;

$X_{23}$  is absent or a basic residue;

$Z_1$  is  $H_2N-$  ;

$Z_2$  is  $-C(O)NRR$  or  $-C(O)OR$ ;

each R is independently -H, ( $C_1$ - $C_6$ ) alkyl, ( $C_1$ - $C_6$ ) alkenyl, ( $C_1$ - $C_6$ ) alkynyl, ( $C_5$ - $C_{20}$ ) aryl, ( $C_6$ - $C_{26}$ ) alkaryl, 5-20 membered heteroaryl or 6-26 membered alkheteroaryl or a 1 to 7-residue peptide or peptide analogue in which one or more bonds between residues 1-7 are independently a substituted amide, an isostere of an amide or an amide mimetic; and

each “-” between residues  $X_1$  to  $X_{23}$  and between residues of the peptide to  $Z_2$  independently designates an amide linkage, a substituted amide linkage, an isostere of an amide or an amide mimetic; or

an N- terminally blocked form, a C-terminally blocked form, or an N- and C-terminally blocked form of formula (I).

2-55. (canceled)

56. (previously presented) The 15 to 26-residue peptide or deleted peptide analogue of Claim 1, in which one helical turn is deleted.

57. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 1, in which three, four, six, seven or eight residues  $X_1$  ,  $X_2$  ,  $X_3$  ,  $X_4$  ,  $X_5$  ,  $X_6$  ,  $X_7$  ,  $X_8$  ,  $X_9$  ,  $X_{10}$  ,  $X_{11}$  ,  $X_{12}$  ,  $X_{13}$  ,  $X_{14}$  ,  $X_{15}$  ,  $X_{16}$  ,  $X_{17}$  ,  $X_{18}$  ,  $X_{19}$  ,  $X_{20}$  ,  $X_{21}$  and  $X_{22}$  are deleted.

58. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 57, in which 3 consecutive residues are deleted.

59. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 57, in which 4 consecutive residues are deleted.

60. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 57, in which two non-contiguous sets of 3 consecutive residues are deleted.

61. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 57, in which two non-contiguous sets of 4 consecutive residues are deleted.

62. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 57, in which one set of 3 consecutive residues and one set of 4 consecutive residues are deleted.
63. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 57, in which 6, 7 or 8 consecutive residues are deleted.
- 64-66. (canceled)
67. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 1 in which:  
the “-” between residues designates -C (O) NH- ;  
 $Z_1$  is  $H_2N^-$  ; and  
 $Z_2$  is -C (O) OH or a salt thereof.
68. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 1, in which the mean hydrophobic moment,  $\langle\mu_H\rangle$ , is 0.45 to 0.65.
69. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 68, in which the mean hydrophobic moment,  $\langle\mu_H\rangle$ , is 0.50 to 0.60.
70. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 1, in which the mean hydrophobicity,  $\langle H_o \rangle$ , is -0.050 to -0.070.
71. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 1, in which the mean hydrophobicity,  $\langle H_o \rangle$ , is -0.030 to -0.055.
72. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 1, in which the mean hydrophobicity of the hydrophobic face,  $\langle H_o^{pho} \rangle$ , is 0.90 to 1.20.
73. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 72, in which the mean hydrophobicity of the hydrophobic face,  $\langle H_o^{pho} \rangle$ , is 0.94 to 1.10.
74. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 1, in which the pho angle is 160° to 220°.

75. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 74, in which the pho angle is 180° to 200°.

76-78. (canceled)

79. (previously presented) A pharmaceutical composition comprising an ApoA-I agonist compound and a pharmaceutically acceptable carrier, excipient or diluent, wherein the ApoA-I agonist compound is a 15 to 26-residue peptide or peptide analogue according to Claim 1 or 57.

80-81. (canceled)

82. (previously presented) The pharmaceutical composition of Claim 79 which is a lyophilized powder.

83. (previously presented) The pharmaceutical composition of Claim 79 which is a solution.

84. (previously presented) The N-terminally blocked form of the 15 to 26-residue peptide or peptide analogue of Claim 1.

85. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 84 in which the N-terminally blocking group is selected from the group consisting of acetyl, formyl and dansyl.

86. (previously presented) The C-terminally blocked form of the 15 to 26-residue peptide or peptide analogue of Claim 1.

87. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 86 in which the C-terminally blocking group is methyl.

88. (previously presented) The N-terminally and C-terminally blocked form of the 15 to 26-residue peptide or peptide analogue of Claim 1.